Safety and Efficacy of DCB for the Treatment of SFA Ischemic Vascular Disease in Patients With TASC C and D Lesions

Ettore Sansavini Health Science Foundation150 enrolled

Overview

The study is aimed at collecting preliminary safety and efficacy data related to the use of Drug Coated Balloon (DCB) technology for the treatment of symptomatic Superficial Femoral Artery (SFA) ischemic vascular disease in patients presenting with long lesions. The present clinical evaluation is intended as a prospective observational data collection of patient treatment in full accordance with institution standard practice and utilizing an approved (CE marked) DCB currently available on the market.

The present study is designed as a prospective, open label, observational study. The study will collect information about the medical care patients receive during their planned procedure. No additional testing or procedures will be done. Patients elected for endovascular revascularization with DCB will be asked their written consent to the use of their personal data. Revascularization will be performed as per standard procedure of the sites. After discharge all patients will attend clinic visits at 30 days (±14 days), 6 months (±30 days), 12 months (±30 days), 24 and 36 months (±30 days). Angiographic follow-up will be performed in symptomatic patients, as clinically indicated.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

PAD

Interventions

Drug Coated BalloonDEVICE

Peripheral PTA with a drug coated balloon

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Documented obstructive ischemic, symptomatic arterial disease in the femoral-popliteal arteries according to Rutherford Category 2, 3 or 4 2. Target lesion consists of a single solitary or multiple adjacent de novo or re-stenotic lesions (non-in-stent) with diameter stenosis ≥ 70% by visual estimate and cumulative lesion length ≥ 15 cm 3. Target vessel is the superficial femoral artery and/or popliteal artery (P1-2-3) 4. Life expectancy \>1 year in the Investigator's opinion 5. Written informed consent Exclusion Criteria: 1. Patient unwilling or unlikely to comply with FU schedule 2. Administration of local or systemic thrombolytic therapy within 48 hours prior to the index procedure 3. Known allergies or sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or paclitaxel 4. Additional planned cardiac or peripheral percutaneous or surgical intervention including CABG within 30 days following the study procedure 5. ≥15 cm long inflow lesion (≥50% DS) 6. Failure to successfully treat \< 15 cm long inflow lesion in the ipsilateral Iliac artery

Locations (10)

Casa di Cura Montevergine

Mercogliano, Avellino, Italy

NOT_YET_RECRUITING

ICLAS

Rapallo, Genova, Italy

ACTIVE_NOT_RECRUITING

Maria Cecilia Hospital

Cotignola, Ravenna, Italy

Outcomes

Primary Outcomes

Rate of primary patency

Primary patency is defined as freedom from the combined endpoints of clinically-driven target lesion revascularization (TLR) and \>50% restenosis in the treated lesion.

Time frame: 12 months after percutaneous treatment